On January 26, it was reported that Livzon Group (000513/01513) announced that the application for domestic drug production registration of the recombinant human follicle - stimulating hormone injection developed by its holding subsidiary, Zhuhai Livzon Mab Biotech Co., Ltd., has been accepted by the National Medical Products Administration. The specification of the accepted drug is 33μg (450IU)/0.75mL, and the registration category is 3.3 for therapeutic biological products. According to the announcement, the cumulative R & D cost of the recombinant human follicle - stimulating hormone injection has reached 104 million yuan.

The announcement mentioned that the indications of the recombinant human follicle - stimulating hormone injection include anovulatory women, superovulation in assisted reproductive technology, and patients with severe luteinizing hormone and follicle - stimulating hormone deficiencies. The market demand for the drug has been continuously increasing due to the annual rise in the domestic infertility rate. In 2023, the domestic terminal sales amount of follicle - stimulating hormone drugs was 2.637 billion yuan, and the sales amount from January to September 2024 was 2.112 billion yuan, with recombinant human follicle - stimulating hormone drugs accounting for more than 70% of the total.

In the first three quarters of 2024, Livzon Group achieved revenue of 9.082 billion yuan and a net profit attributable to the parent company of 1.673 billion yuan.

Source: https://finance.eastmoney.com/a/202501263308467816.html